A role for liposomes in genetic vaccination
- PMID: 12477411
- DOI: 10.1016/s0264-410x(02)00514-5
A role for liposomes in genetic vaccination
Abstract
Genetic immunization by the use of plasmid DNA encoding antigens from bacteria, viruses, protozoa and cancers has often led to protective humoral and cell-mediated immunity, and has some practical advantages over conventional vaccines. However, naked DNA vaccines can be degraded by nucleases in situ, are unable to target antigen presenting cells (APCs), and exhibit poor performance when administered by routes other than the intramuscular, all of which have reduced the value of the approach. We have been able to avoid DNA degradation and also target DNA to APCs by the use of liposomes as DNA vaccine carriers. Entrapment of plasmid DNA within the aqueous spaces of cationic liposomes is effected by a one step procedure which results in most of the DNA being incorporated into a freeze dried, ready to use preparation. Animal experiments have shown that immunization by the intramuscular or the subcutaneous route with liposome-entrapped plasmid DNA encoding the hepatitis B surface antigen leads to much greater humoral (IgG subclasses) and cell mediated (splenic IFN-gamma) immune responses than with naked DNA. In other experiments with a plasmid DNA encoding a model antigen (ovalbumin), a cytotoxic T lymphocyte (CTL) response was also observed. These results could be explained by the ability of liposomes to protect their DNA content from local nucleases and direct it to APCs in the lymph nodes draining the injected site.
Similar articles
-
Liposome-mediated DNA vaccination: the effect of vesicle composition.Vaccine. 2001 Apr 30;19(23-24):3301-10. doi: 10.1016/s0264-410x(00)00432-1. Vaccine. 2001. PMID: 11312029
-
Intranasal immunization with liposome-encapsulated plasmid DNA encoding influenza virus hemagglutinin elicits mucosal, cellular and humoral immune responses.J Clin Virol. 2004 Dec;31 Suppl 1:S99-106. doi: 10.1016/j.jcv.2004.09.013. J Clin Virol. 2004. PMID: 15567101
-
Liposome-mediated DNA immunisation via the subcutaneous route.J Drug Target. 2003;11(8-10):555-63. doi: 10.1080/10611860410001670071. J Drug Target. 2003. PMID: 15203925
-
DNA vaccines: a role for liposomes.Curr Opin Mol Ther. 1999 Feb;1(1):39-42. Curr Opin Mol Ther. 1999. PMID: 11249682 Review.
-
Non-viral vector as vaccine carrier.Adv Genet. 2005;54:315-37. doi: 10.1016/S0065-2660(05)54013-6. Adv Genet. 2005. PMID: 16096017 Review.
Cited by
-
Cationic Nanostructures for Vaccines Design.Biomimetics (Basel). 2020 Jul 7;5(3):32. doi: 10.3390/biomimetics5030032. Biomimetics (Basel). 2020. PMID: 32645946 Free PMC article. Review.
-
Treatment with mANT2 shRNA enhances antitumor therapeutic effects induced by MUC1 DNA vaccination.Mol Ther. 2011 May;19(5):979-89. doi: 10.1038/mt.2010.235. Epub 2010 Nov 9. Mol Ther. 2011. PMID: 21063392 Free PMC article.
-
Pulmonary DNA vaccination: concepts, possibilities and perspectives.J Control Release. 2005 Sep 20;107(1):1-29. doi: 10.1016/j.jconrel.2005.05.028. J Control Release. 2005. PMID: 16054263 Free PMC article. Review.
-
Lipid-Based Particles: Versatile Delivery Systems for Mucosal Vaccination against Infection.Front Immunol. 2018 Mar 7;9:431. doi: 10.3389/fimmu.2018.00431. eCollection 2018. Front Immunol. 2018. PMID: 29563912 Free PMC article. Review.
-
Protective effect of DNA-mediated immunization with liposome-encapsulated GRA4 against infection of Toxoplasma gondii.J Zhejiang Univ Sci B. 2009 Jul;10(7):512-21. doi: 10.1631/jzus.B0820300. J Zhejiang Univ Sci B. 2009. PMID: 19585669 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous